Clinical trials: Gastrointestinal Infection
Hepatitis C
Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01909804
- Testing
- SOF, VEL, RBV
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 323 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been…
- Trial name
- NCT01641926
- Testing
- PEG-Intron™, PEGASYS™
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan.
- Trial name
- NCT00200343
- Testing
- Ursodeoxycholic acid 150mg / day, Ursodeoxycholic acid 600mg / day, Ursodeoxycholic acid 900mg / day
- Where
- Japan
- Volunteers
- 596 people
- Sponsor
- Tanabe Pharma Corporation
HCV Infection
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of…
- Trial name
- NCT00890318
- Testing
- ABT-072, ketoconazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Abbott
Hepatitis B
Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs
To evaluate the persistence of antibodies against hepatitis B at 30, 42, 54 and 66 months after the first dose of the hepatitis B primary vaccination course.
- Trial name
- NCT00343915
- Testing
- Engerix™-B (thiomersal-free) 20µg, 10 μg Engerix™-B (preservative-free)
- Where
- 4 sites in Australia, Belgium and 1 more
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Hepatitis B, Chronic
A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B
This study is divided into two parts. Phase Ib is a randomized, double-blind, placebo-controlled trial, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, preliminary efficacy, and immunogenicity of…
- Trial name
- NCT06452693
- Testing
- Nucleotide drugs Control group
- Where
- 22 sites in China
- Volunteers
- 162 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis C, Chronic
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype…
- Trial name
- NCT01435226
- Testing
- GS-5885, GS-9451, tegobuvir
- Where
- 51 sites in United States, Germany
- Volunteers
- 170 people
- Sponsor
- Gilead Sciences
Liver Fibrosis, HEPATITIS B CHRONIC
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)
- Conditions
- Liver Fibrosis, HEPATITIS B CHRONIC, Hepatocellular Carcinoma
- Trial name
- NCT02289300
- Testing
- DCB-BO1202
- Where
- Taiwan
- Sponsor
- A2 Healthcare Taiwan Corporation
Hepatitis C, Chronic
Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)
Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)
- Trial name
- NCT01081158
- Testing
- Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron), Drug: SCH 900518 Biologic: Peginterferon alfa-2b, Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C
The purpose of this open-label study is to assess the safety, antiviral activity, and pharmacokinetics of 9 subcutaneous injections of miravirsen monotherapy (5 weekly doses over 5 weeks, followed by a further 4 doses once every…
- Trial name
- NCT01727934
- Testing
- Miravirsen sodium
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Santaris Pharma A/S
Hepatitis C, Chronic
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus.
- Trial name
- NCT01200225
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO), work productivity and safety data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), ±…
- Trial name
- VERITAS (NCT02636608)
- Volunteers
- 244 people
- Sponsor
- AbbVie
Neoplasms, Liver
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 (Pexa-Vec) injected within hepatic carcinoma tumors.
- Trial name
- NCT00629759
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Jennerex Biotherapeutics
Chronic Graft-Versus-Host Disease (cGVHD)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD.
- Trial name
- NCT06619561
- Testing
- Vimseltinib
- Where
- 26 sites in United States
- Volunteers
- 48 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Chronic Hepatitis C
Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.
- Trial name
- NCT00823862
- Testing
- SD-101, ribavirin
- Where
- 5 sites in Poland
- Volunteers
- 34 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis C
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
This is a randomized, three-part, parallel-group, open-label trial of grazoprevir (MK-5172) (100 mg) and uprifosbuvir (MK-3682) (300 mg or 450 mg) with either elbasvir (MK-8742) (50 mg) or ruzasvir (MK-8408) (60 mg), and with or…
- Trial name
- NCT02332720
- Testing
- Grazoprevir, Uprifosbuvir, Elbasvir
- Volunteers
- 413 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
The main objective of this study is to establish interferon-beta-1a as the treatment of choice for chronic Hepatitis C with better efficacy and safety profiles in monotherapy or combination therapy.
- Trial name
- NCT00249860
- Testing
- Interferon-beta-1a, Ribavirin plus Interferon-beta-1a
- Volunteers
- 257 people
- Sponsor
- EMD Serono
Hepatitis B, Infectious Disease
A Study in Healthy Volunteers
This is three part study that will, in part one assess the safety, tolerability, and PK of a single dose of CRV431 in healthy volunteers.
- Conditions
- Hepatitis B, Infectious Disease, Liver Diseases
- Trial name
- NCT03596697
- Testing
- CRV431, TDF
- Where
- 3 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Hepion Pharmaceuticals, Inc.
Hepatitis C, Chronic
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)
This is a study to determine the pharmacokinetics (PK) and weight-based dose of boceprevir following single oral dose administration in Chronic Hepatitis C Virus (HCV) pediatric participants.
- Trial name
- NCT01425190
- Testing
- Boceprevir
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.